PAVmed

PAVM

Market cap $10M

Recognized as the leading company in its size category in program honoring the top workplaces across the diagnostics and precision-medicine sectors NEW YORK , Nov. 20, 2025 /PRNewswire/ --  Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it has been named the winner in its company size category of the GenomeWeb 2025 Best Places to Work program, one of five top-ranking honorees across the life sciences research, diagnostics and precision medicine sectors. GenomeWeb  is the leading news organization serving the global community of professionals in molecular biology research and molecular diagnostics.

PAVmed Inc. ( PAVM ) Q3 2025 Earnings Call November 13, 2025 8:30 AM EST Company Participants Matt Riley Lishan Aklog - Chairman & CEO Dennis McGrath - President & CFO Conference Call Participants Anthony Vendetti - Maxim Group LLC, Research Division Presentation Operator Good morning, and welcome to the PAVmed's Third Quarter 2025 Business Update Conference Call. [Operator Instructions] This call is being recorded on Thursday, November 13, 2025.

NEW YORK , Nov. 13, 2025 /PRNewswire/ --  Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, being held November 20, 2025 in New York City. Dennis McGrath, Lucid's Chief Financial Officer, will be available for one-on-one meetings with investors.

Veris Health launched commercial phase of strategic partnership and relaunched development of implantable physiological monitor PAVmed signed letter of intent (LOI) to license groundbreaking endoscopic esophageal imaging technology Conference call and webcast to be held today, November 13, at 8:30 AM EST NEW YORK , Nov. 13, 2025 /PRNewswire/ --  PAVmed Inc.  (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid") and Veris Health Inc. ("Veris"), and reported financial results for the quarter ended September 30, 2025. Conference Call and Webcast The webcast will take place on Thursday, November 13, 2025, at 8:30 AM and is accessible in the investor relations section of the Company's website at pavmed.com.

Processed 2,841 EsoGuard® tests and recognized 3Q25 revenue of $1.2 million, ending quarter with over $47 million in proforma cash and extending runway through 2026 and well past upcoming reimbursement milestones Multi-Jurisdictional Contractor Advisory Committee (CAC) meeting on Medicare Local Coverage Determination (LCD) for Lucid's EsoGuard yielded unanimous expert consensus supporting Medicare coverage Conference call and webcast to be held today, November 12, at 8:30 AM EST NEW YORK , Nov. 12, 2025 /PRNewswire/ --  Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM) ("PAVmed"), today provided a business update for the Company and reported financial results for the three months ended September 30, 2025. Conference Call and Webcast The webcast will take place on Wednesday, November 12, 2025, at 8:30 AM and will be accessible in the investor relations section of the Company's website at luciddx.com.

Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , Oct. 30, 2025 /PRNewswire/ -- PAVmed Inc.  (Nasdaq: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Thursday, November 13, 2025, at 8:30 AM ET. During the call,  Lishan Aklog, M.D.

Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , Oct. 29, 2025 /PRNewswire/ --  Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Wednesday, November 12, 2025, at 8:30 AM ET. During the call,  Lishan Aklog, M.D.

NEW YORK , Oct. 15, 2025 /PRNewswire/ --  Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will participate in the 2025 Maxim Growth Summit, being held October 22-23, 2025 in New York City. Dennis McGrath, Lucid's Chief Financial Officer, will host one-on-one meetings throughout the conference.

PAVmed (PAVM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

The Veris Cancer Care Platform to be deployed to enhance personalized cancer care in patients undergoing systemic cancer therapy across OSUCCC – James NEW YORK , Oct. 7, 2025 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company") a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its majority-owned digital health subsidiary Veris Health Inc. ("Veris"), today announced that Veris and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J.